• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• BL Club
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

New Delhi, Dec 3 Ranbaxy Laboratories Ltd announced that it has signed an exclusive agreement with BioPro Pharmaceutical Inc for marketing a brain tumor drug – Gliadel- in India.

Commenting on the development, Mr Sanjeev I. Dani, Senior Vice-President & Regional Director, Asia & CIS, Ranbaxy said, “We are pleased to bring this lifesaving, high technology product to Indian patients. We are working with BioPro to create a productive relationship by complementing each other’s strengths. The licensing agreement, and subsequent launch approval, should enable Ranbaxy to further strengthen its position in the oncology segment.”

Gliadel Wafer is indicated in newly diagnosed patients with high-grade malignant glioma as an adjunct to surgery and radiation. It is also indicated in recurrent glioblastoma multiforme patients as an adjunct to surgery. Gliadel is the only US FDA-approved chemotherapeutic implant for use during surgical resection, providing localised delivery of chemotherapy directly into the cavity created when a brain tumor is removed during surgery.

The product is manufactured by MGI Pharma. BioPro retains the marketing rights in some Asian countries including China, Hong Kong, Taiwan, Korea, Singapore, Indonesia, the Philippines, Malaysia, Thailand, and India.

Though there is very limited data available on the incidence of brain tumors in India, according to unofficial sources, the estimated prevalence of CNS tumors in India is 2-5 new cases per 1,00,000 a year.

More Stories on : Alliances & Joint Ventures | Pharmaceuticals | Ranbaxy Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line